Synthesis and biological evaluation of 4-nitro-substituted 1,3-diaryltriazenes as a novel class of potent antitumor agents. 2011

Tamara Cimbora-Zovko, and Anamaria Brozovic, and Ivo Piantanida, and Gerhard Fritz, and Andrej Virag, and Branko Alič, and Vita Majce, and Marijan Kočevar, and Slovenko Polanc, and Maja Osmak
Division of Molecular Biology, Ruđer Bošković Institute, Bijenička cesta 54, HR-10000 Zagreb, Croatia.

We describe the synthesis and biological activity of a new class of 1,3-diaryltriazenes, namely 4-nitro-substituted 1,3-diaryltriazenes. Structure-activity relationship analysis reveals that 1,3-diaryltriazenes can be modified from inactive to highly cytotoxic compounds by the introduction of two nitro groups at the para positions of benzene rings and two additional electron-withdrawing groups (bromo, chloro, trifluoromethyl or fluoro substituents) at their ortho position. In order to increase the solubility of the modified compounds, we introduced various acyl groups to their triazene nitrogen. The results of LC-MS/MS analysis showed that N-acyltriazenes can be considered as prodrugs of non-acylated triazenes. Selected 3-acetyl-1,3-bis(2-chloro-4-nitrophenyl)-1-triazene (8b) is highly cytotoxic against different tumor cell lines, including cisplatin-resistant laryngeal carcinoma cells. Notably, its antiproliferative activity is significantly higher against tumor cells than against normal cells. DNA binding analysis suggests that neither 8b nor its non-acylated derivative 8a bind into the minor groove of DNA. Instead, 8b induces reactive oxygen species that could provoke endoplasmic reticulum (ER(a)) stress finally leading to apoptosis. Our data suggest that 4-nitro-substituted 1,3-diaryltriazenes are a new class of anticancer molecules which preferentially target malignant cells and may serve as potential antitumor agents.

UI MeSH Term Description Entries
D009596 Nitrophenols PHENOLS carrying nitro group substituents. Nitrophenol
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014226 Triazenes Compounds with three contiguous nitrogen atoms in linear format, H2N-N Diazoamino Compounds,Compounds, Diazoamino
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D017382 Reactive Oxygen Species Molecules or ions formed by the incomplete one-electron reduction of oxygen. These reactive oxygen intermediates include SINGLET OXYGEN; SUPEROXIDES; PEROXIDES; HYDROXYL RADICAL; and HYPOCHLOROUS ACID. They contribute to the microbicidal activity of PHAGOCYTES, regulation of SIGNAL TRANSDUCTION and GENE EXPRESSION, and the oxidative damage to NUCLEIC ACIDS; PROTEINS; and LIPIDS. Active Oxygen Species,Oxygen Radical,Oxygen Radicals,Pro-Oxidant,Reactive Oxygen Intermediates,Active Oxygen,Oxygen Species, Reactive,Pro-Oxidants,Oxygen, Active,Pro Oxidant,Pro Oxidants,Radical, Oxygen

Related Publications

Tamara Cimbora-Zovko, and Anamaria Brozovic, and Ivo Piantanida, and Gerhard Fritz, and Andrej Virag, and Branko Alič, and Vita Majce, and Marijan Kočevar, and Slovenko Polanc, and Maja Osmak
October 2020, Chemical biology & drug design,
Tamara Cimbora-Zovko, and Anamaria Brozovic, and Ivo Piantanida, and Gerhard Fritz, and Andrej Virag, and Branko Alič, and Vita Majce, and Marijan Kočevar, and Slovenko Polanc, and Maja Osmak
September 2018, Molecules (Basel, Switzerland),
Tamara Cimbora-Zovko, and Anamaria Brozovic, and Ivo Piantanida, and Gerhard Fritz, and Andrej Virag, and Branko Alič, and Vita Majce, and Marijan Kočevar, and Slovenko Polanc, and Maja Osmak
February 2017, Bioorganic & medicinal chemistry letters,
Tamara Cimbora-Zovko, and Anamaria Brozovic, and Ivo Piantanida, and Gerhard Fritz, and Andrej Virag, and Branko Alič, and Vita Majce, and Marijan Kočevar, and Slovenko Polanc, and Maja Osmak
June 1983, Journal of medicinal chemistry,
Tamara Cimbora-Zovko, and Anamaria Brozovic, and Ivo Piantanida, and Gerhard Fritz, and Andrej Virag, and Branko Alič, and Vita Majce, and Marijan Kočevar, and Slovenko Polanc, and Maja Osmak
June 2015, Archives of pharmacal research,
Tamara Cimbora-Zovko, and Anamaria Brozovic, and Ivo Piantanida, and Gerhard Fritz, and Andrej Virag, and Branko Alič, and Vita Majce, and Marijan Kočevar, and Slovenko Polanc, and Maja Osmak
May 2014, European journal of medicinal chemistry,
Tamara Cimbora-Zovko, and Anamaria Brozovic, and Ivo Piantanida, and Gerhard Fritz, and Andrej Virag, and Branko Alič, and Vita Majce, and Marijan Kočevar, and Slovenko Polanc, and Maja Osmak
March 1998, Journal of medicinal chemistry,
Tamara Cimbora-Zovko, and Anamaria Brozovic, and Ivo Piantanida, and Gerhard Fritz, and Andrej Virag, and Branko Alič, and Vita Majce, and Marijan Kočevar, and Slovenko Polanc, and Maja Osmak
May 2015, Bioorganic & medicinal chemistry,
Tamara Cimbora-Zovko, and Anamaria Brozovic, and Ivo Piantanida, and Gerhard Fritz, and Andrej Virag, and Branko Alič, and Vita Majce, and Marijan Kočevar, and Slovenko Polanc, and Maja Osmak
August 2012, European journal of medicinal chemistry,
Tamara Cimbora-Zovko, and Anamaria Brozovic, and Ivo Piantanida, and Gerhard Fritz, and Andrej Virag, and Branko Alič, and Vita Majce, and Marijan Kočevar, and Slovenko Polanc, and Maja Osmak
January 2018, European journal of medicinal chemistry,
Copied contents to your clipboard!